Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

NEW HAVEN, Conn., Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November. 3rd Chief Commercial Officer Summit October 23-24, 2024, Philadelphia, P ...